专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2009071696A3 HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31 审中-公开
标题翻译： IL-31特异的人体抗体分子
公开(公告)号：WO2009071696A3
公开(公告)日：2009-09-03
申请号：PCT/EP2008067024
申请日：2008-12-08
申请人： ZYMOGENETICS INC , BONDENSGAARD KENT , BECKMANN ROLAND
发明人： BONDENSGAARD KENT , BECKMANN ROLAND
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要： The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
摘要翻译：本发明提供能够结合IL-31的人源化小鼠抗人IL-31抗体和抗体片段，从而中和，抑制，限制或降低IL-31的促炎症或促瘙痒作用。

82. 发明申请

WO2007149981A8 METHODS OF GENE EXPRESSION ANALYSIS 审中-公开
标题翻译：基因表达分析方法
公开(公告)号：WO2007149981A8
公开(公告)日：2009-08-06
申请号：PCT/US2007071778
申请日：2007-06-21
申请人： ZYMOGENETICS INC , WHITMORE THEODORE E
发明人： WHITMORE THEODORE E
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6809 , C12Q1/6837 , C12Q2565/501 , C12Q2537/143 , C12Q2563/149
摘要： The present invention relates to methods for cost effective, high throughput, multiplexed nucleic acid (gene) expression analysis using photobiotin-labeled anti-sense RNA (aRNA) as hybridization probes in conjunction with a multiplex capable system. The use of the relatively inexpensive photobiotin provides a cost effective alternative to the use of currently available, expensive biotin analogs or other nonradioisotopic labeling methods.
摘要翻译：本发明涉及使用光生物素标记的反义RNA（aRNA）作为杂交探针与多重能力系统结合的成本有效，高通量，多重核酸（基因）表达分析的方法。相对廉价的光生物素的使用提供了使用当前可用的，昂贵的生物素类似物或其他非放射性同位素标记方法的成本有效的替代方案。

83. 发明申请

WO2009058870A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES 审中-公开
标题翻译：用于调节免疫应答的组合物和方法
公开(公告)号：WO2009058870A1
公开(公告)日：2009-05-07
申请号：PCT/US2008/081591
申请日：2008-10-29
申请人： ZYMOGENETICS, INC. , LEVIN, Steven, D. , RAMSDELL, Frederick, J. , HOWARD, Edward, D. , TAFT, David, W. , RIXON, Mark, W. , HEBB, Luanne
发明人： LEVIN, Steven, D. , RAMSDELL, Frederick, J. , HOWARD, Edward, D. , TAFT, David, W. , RIXON, Mark, W. , HEBB, Luanne
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K2039/505
摘要： Disclosed is a newly identified CD28 family member that functions as lymphocyte inhibitory receptor termed pG6b, which is expressed on T cells. Methods and compositions for modulating pG6b-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic, and research purposes are also disclosed.
摘要翻译：公开了一种新鉴定的CD28家族成员，其作为称为pG6b的淋巴细胞抑制性受体，其在T细胞上表达。还公开了用于调节pG6b介导的负信号并且干扰其反受体用于治疗，诊断和研究目的的相互作用的方法和组合物。

84. 发明申请

WO2009052293A1 COMBINATION OF BLYS INHIBITION AND ANTI-CD 20 AGENTS FOR TREATMENT OF AUTOIMMUNE DISEASE 审中-公开
标题翻译：用于治疗自身免疫疾病的组织抑制和抗CD 20药物的组合
公开(公告)号：WO2009052293A1
公开(公告)日：2009-04-23
申请号：PCT/US2008/080177
申请日：2008-10-16
申请人： ZYMOGENETICS, INC. , ARES TRADING S.A. , PONCE, JR., Raphael, A. , BROLY, Herve , GRAFFNER, Hans Otto Lennart , PEANO, Sergio
发明人： PONCE, JR., Raphael, A. , BROLY, Herve , GRAFFNER, Hans Otto Lennart , PEANO, Sergio
IPC分类号： A61K38/17 , A61K39/395 , C07K19/00 , C07K16/28 , A61P37/00
CPC分类号： A61K39/3955 , A61K38/1709 , A61K38/1793 , A61K39/395 , A61K39/39541 , A61K45/06 , A61K2300/00
摘要： The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and anti-CD20 agents for the treatment of autoimmune diseases. One preferred method is where the BLyS antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of anti-CD20 agents contemplated include RITUXAN®, ocrelizumab, ofatumumab (HuMax-CD20®), TRU-015, and DXL625, although any agent that binds to CD 20 may be suitable. The methods of the present invention reduce the levels of B cells in patients in need of such reduction, such as those suffering from autoimmune diseases.
摘要翻译：本发明涉及涉及BLyS或BLyS / APRIL抑制的新型联合疗法和用于治疗自身免疫性疾病的抗CD20剂。一种优选的方法是其中BLyS拮抗剂是Fc-融合蛋白，其可以是包含TACI的胞外结构域或其功能片段的TACI-Fc-融合蛋白，包含细胞外结构域的BAFF-R-Fc-融合蛋白 BAFF-R或其功能片段，或包含BCMA细胞外结构域的BCMA-Fc-融合蛋白或其功能片段。在本发明的方法中，考虑到一些抗CD20剂包括RITUXAN，ocrelizumab，噻吗单抗（HuMax-CD20），TRU-015和DXL625，尽管与CD20结合的任何试剂可能是合适的。本发明的方法降低了需要这种还原的患者中的B细胞的水平，例如患有自身免疫性疾病的患者。

85. 发明申请

WO2008133684A8 ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 审中-公开
公开(公告)号：WO2008133684A8
公开(公告)日：2008-11-06
申请号：PCT/US2007/067637
申请日：2007-04-27
申请人： ZYMOGENETICS, INC. , JASPERS, Stephen, R. , PRESNELL, Scott, R. , RIXON, Mark, W. , LEVIN, Steven, D. , HUBER, Monica
发明人： JASPERS, Stephen, R. , PRESNELL, Scott, R. , RIXON, Mark, W. , LEVIN, Steven, D. , HUBER, Monica
IPC分类号： C07K16/24 , C12N5/18 , A61K39/395 , A61P35/00 , A61P37/06 , A61P31/00
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.

86. 发明申请

WO2008133684A1 ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME 审中-公开
标题翻译：与IL-17A和IL-17F两个结合的抗体及其使用方法
公开(公告)号：WO2008133684A1
公开(公告)日：2008-11-06
申请号：PCT/US2007067637
申请日：2007-04-27
申请人： ZYMOGENETICS INC , JASPERS STEPHEN R , PRESNELL SCOTT R , RIXON MARK W , LEVIN STEVEN D , HUBER MONICA
发明人： JASPERS STEPHEN R , PRESNELL SCOTT R , RIXON MARK W , LEVIN STEVEN D , HUBER MONICA
IPC分类号： C07K16/24 , A61K39/395 , A61P31/00 , A61P35/00 , A61P37/06 , C12N5/18
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/31 , C07K2317/76
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, an methods of using the same in inflammation.
摘要翻译：本发明涉及阻断，抑制，减少，拮抗或中和IL-17A和IL-17F的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。本发明包括结合IL-17A和IL-17F的抗体，产生抗体的杂交瘤，在炎症中使用该抗体的方法。

87. 发明申请

WO2008086505A3 METHODS OF USING IL-31 TO TREAT AIRWAY HYPER-RESPONSIVENESS AND ASTHMA 审中-公开
标题翻译：使用IL-31治疗气道超敏反应和哮喘的方法
公开(公告)号：WO2008086505A3
公开(公告)日：2008-10-23
申请号：PCT/US2008050815
申请日：2008-01-10
申请人： ZYMOGENETICS INC , BILSBOROUGH JANINE , BORT SUSAN J , CHADWICK ERIC M , MUDRI SHERRI L , YAO YUE , BANNINK KENNETH M , MEEHAN WOERNER P , REN HONG PING
发明人： BILSBOROUGH JANINE , BORT SUSAN J , CHADWICK ERIC M , MUDRI SHERRI L , YAO YUE , BANNINK KENNETH M , MEEHAN WOERNER P , REN HONG PING
IPC分类号： A61K38/20 , A61P11/00 , A61P11/06
CPC分类号： A61K38/20
摘要： Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
摘要翻译：使用IL-31激动剂，包括IL-31，用于治疗激动剂用于治疗哮喘，气道高反应性或过敏性鼻炎。该方法包括抑制，减少，限制或最小化促炎细胞因子的产生，并且包括在致敏或攻击期间施用IL-31激动剂，导致哮喘，气道高反应性或过敏性鼻炎状态。

88. 发明申请

WO2008118930A1 SOLUBLE IL-17RA/RC FUSION PROTEINS AND RELATED METHODS 审中-公开
标题翻译：可溶性IL-17RA / RC融合蛋白及相关方法
公开(公告)号：WO2008118930A1
公开(公告)日：2008-10-02
申请号：PCT/US2008/058190
申请日：2008-03-26
申请人： ZYMOGENETICS, INC. , LEVIN, Steven D. , RIXON, Mark W. , GAO, Zeren
发明人： LEVIN, Steven D. , RIXON, Mark W. , GAO, Zeren
IPC分类号： C07K14/435
CPC分类号： C07K14/7155 , A61K2039/505 , C07K16/2866 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C07K2319/32
摘要： Disclosed are antagonists of IL-17A and IL-17F. The antagonists are based on soluble IL-17RA and IL-17RC fusion proteins, including hybrid soluble receptors comprising portions of both IL-17RC and IL-17RA ("IL-17RC/IL-17RA"). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. Also disclosed are methods of using such antagonists for treating disease, particularly inflammatory diseases mediated at least in part by IL-17A and/or IL-17F.
摘要翻译：公开了IL-17A和IL-17F的拮抗剂。拮抗剂基于可溶性IL-17RA和IL-17RC融合蛋白，包括包含IL-17RC和IL-17RA（“IL-17RC / IL-17RA”）部分的杂合可溶性受体。这种拮抗剂用于阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者的活性。还公开了使用这种拮抗剂治疗疾病，特别是至少部分地由IL-17A和/或IL-17F介导的炎性疾病的方法。

89. 发明申请

WO2008086505A2 METHODS OF USING IL-31 TO TREAT AIRWAY HYPER-RESPONSIVENESS AND ASTHMA 审中-公开
标题翻译：使用IL-31治疗气道高反应性和ASTHMA的方法
公开(公告)号：WO2008086505A2
公开(公告)日：2008-07-17
申请号：PCT/US2008/050815
申请日：2008-01-10
申请人： ZYMOGENETICS, INC. , BILSBOROUGH, Janine , BORT, Susan, J. , CHADWICK, Eric, M. , MUDRI, Sherri, L. , YAO, Yue , BANNINK, Kenneth, M. , MEEHAN, Woerner, P. , REN, Hong Ping
发明人： BILSBOROUGH, Janine , BORT, Susan, J. , CHADWICK, Eric, M. , MUDRI, Sherri, L. , YAO, Yue , BANNINK, Kenneth, M. , MEEHAN, Woerner, P. , REN, Hong Ping
CPC分类号： A61K38/20 , Y02A50/473
摘要： Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
摘要翻译：使用IL-31激动剂，包括IL-31，用于治疗激动剂用于治疗哮喘，气道高反应性或过敏性鼻炎。该方法包括抑制，减少，限制或最小化促炎细胞因子的产生，并且包括在致敏或攻击期间施用IL-31 agonsit，导致哮喘，气道高反应性或过敏性鼻炎状态。

90. 发明申请

WO2007124283A3 TETRAMERIZING POLYPEPTIDES AND METHODS OF USE 审中-公开
标题翻译：聚合多聚物和使用方法
公开(公告)号：WO2007124283A3
公开(公告)日：2008-01-17
申请号：PCT/US2007066607
申请日：2007-04-13
申请人： ZYMOGENETICS INC , WEST JAMES W , BRANDT CAMERON S
发明人： WEST JAMES W , BRANDT CAMERON S
IPC分类号： C07K14/705
CPC分类号： C07K14/70532 , C07K2319/00 , C12P21/02
摘要： The present invention relates to a method of preparing a tetrameric protein comprising culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a vasodialator-stimulated phosphoprotein (VASP) domain and a heterologous protein. In one embodiment, the heterologous protein is a membrane protein, the portion of the heterologous protein that included in the fusion protein is the extracellular domain of that protein, and the resulting fusion protein is soluble. The method can be used to produced homo- and hetero-tetrameric proteins. The present invention also encompasses DNA molecules, expression vectors, and host cells used in the present method and fusion proteins produced by the present method.
摘要翻译：本发明涉及一种制备四聚蛋白的方法，其包括用编码融合蛋白的表达载体转化或转染的宿主细胞，所述融合蛋白包含血管扩张剂刺激的磷蛋白（VASP）结构域和异源蛋白。在一个实施方案中，异源蛋白质是膜蛋白，融合蛋白中包含的异源蛋白质的部分是该蛋白质的细胞外结构域，并且所得的融合蛋白质是可溶的。该方法可用于产生同型和异四聚体蛋白质。本发明还包括本方法中使用的DNA分子，表达载体和宿主细胞以及通过本发明方法产生的融合蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式